BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, Witkin JM. A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies. Neuropsychopharmacology 2016;41:1803-12. [PMID: 26585287 DOI: 10.1038/npp.2015.348] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Calo G, Lambert DG. Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic. Br J Anaesth 2018;121:1105-14. [PMID: 30336855 DOI: 10.1016/j.bja.2018.06.024] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
2 Zaveri NT, Meyer ME. NOP-Targeted Nonpeptide Ligands. Handb Exp Pharmacol 2019;254:37-67. [PMID: 31119463 DOI: 10.1007/164_2019_213] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
3 Young KD, Misaki M, Harmer CJ, Victor T, Zotev V, Phillips R, Siegle GJ, Drevets WC, Bodurka J. Real-Time Functional Magnetic Resonance Imaging Amygdala Neurofeedback Changes Positive Information Processing in Major Depressive Disorder. Biol Psychiatry 2017;82:578-86. [PMID: 28476207 DOI: 10.1016/j.biopsych.2017.03.013] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 10.8] [Reference Citation Analysis]
4 Sanches M, Quevedo J, Soares JC. New agents and perspectives in the pharmacological treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2021;106:110157. [PMID: 33159975 DOI: 10.1016/j.pnpbp.2020.110157] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Masaki C, Sharpley AL, Cooper CM, Godlewska BR, Singh N, Vasudevan SR, Harmer CJ, Churchill GC, Sharp T, Rogers RD, Cowen PJ. Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing. Psychopharmacology (Berl) 2016;233:2655-61. [PMID: 27256357 DOI: 10.1007/s00213-016-4319-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 9.6] [Reference Citation Analysis]
6 Awwad HO, Durand CD, Gonzalez LP, Tompkins P, Zhang Y, Lerner MR, Brackett DJ, Sherry DM, Awasthi V, Standifer KM. Post-blast treatment with Nociceptin/Orphanin FQ peptide (NOP) receptor antagonist reduces brain injury-induced hypoxia and signaling proteins in vestibulomotor-related brain regions. Behav Brain Res 2018;340:183-94. [PMID: 27793733 DOI: 10.1016/j.bbr.2016.10.041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
7 Calo' G, Rizzi A, Ruzza C, Ferrari F, Pacifico S, Gavioli EC, Salvadori S, Guerrini R. Peptide welding technology - A simple strategy for generating innovative ligands for G protein coupled receptors. Peptides 2018;99:195-204. [PMID: 29031796 DOI: 10.1016/j.peptides.2017.10.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
8 Silva AI, Holanda VAD, Azevedo Neto JG, Silva Junior ED, Soares-Rachetti VP, Calo G, Ruzza C, Gavioli EC. Blockade of NOP receptor modulates anxiety-related behaviors in mice exposed to inescapable stress. Psychopharmacology (Berl) 2020;237:1633-42. [PMID: 32095915 DOI: 10.1007/s00213-020-05487-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
9 Moulédous L. The Nociceptin/Orphanin FQ System and the Regulation of Memory. Handb Exp Pharmacol 2019;254:259-78. [PMID: 30430261 DOI: 10.1007/164_2018_185] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Vitale G, Filaferro M, Micioni Di Bonaventura MV, Ruggieri V, Cifani C, Guerrini R, Simonato M, Zucchini S. Effects of [Nphe 1 , Arg 14 , Lys 15 ] N/OFQ-NH 2 (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress. J Psychopharmacol 2017;31:691-703. [DOI: 10.1177/0269881117691456] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
11 Puryear CB, Brooks J, Tan L, Smith K, Li Y, Cunningham J, Todtenkopf MS, Dean RL, Sanchez C. Opioid receptor modulation of neural circuits in depression: What can be learned from preclinical data? Neuroscience & Biobehavioral Reviews 2020;108:658-78. [DOI: 10.1016/j.neubiorev.2019.12.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
12 Gavioli EC, Holanda VAD, Calo G, Ruzza C. Nociceptin/orphanin FQ receptor system blockade as an innovative strategy for increasing resilience to stress. Peptides 2021;141:170548. [PMID: 33862163 DOI: 10.1016/j.peptides.2021.170548] [Reference Citation Analysis]
13 Baruch N, Behrman S, Wilkinson P, Bajorek T, Murphy SE, Browning M. Negative bias in interpretation and facial expression recognition in late life depression: A case control study. Int J Geriatr Psychiatry 2021;36:1450-9. [PMID: 33900662 DOI: 10.1002/gps.5557] [Reference Citation Analysis]
14 Holanda VAD, Medeiros IU, Asth L, Guerrini R, Calo’ G, Gavioli EC. Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness. Psychopharmacology 2016;233:2525-32. [DOI: 10.1007/s00213-016-4310-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
15 Browne CA, Lucki I. Targeting opioid dysregulation in depression for the development of novel therapeutics. Pharmacol Ther 2019;201:51-76. [PMID: 31051197 DOI: 10.1016/j.pharmthera.2019.04.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 14.5] [Reference Citation Analysis]
16 Raddad E, Chappell A, Meyer J, Wilson A, Ruegg CE, Tauscher J, Statnick MA, Barth V, Zhang X, Verfaille SJ. Occupancy of Nociceptin/Orphanin FQ Peptide Receptors by the Antagonist LY2940094 in Rats and Healthy Human Subjects. Drug Metabolism and Disposition 2016;44:1536-42. [DOI: 10.1124/dmd.116.070359] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
17 Litten RZ, Falk DE, Ryan ML, Fertig J, Leggio L. Advances in Pharmacotherapy Development: Human Clinical Studies. In: Grant KA, Lovinger DM, editors. The Neuropharmacology of Alcohol. Cham: Springer International Publishing; 2018. pp. 579-613. [DOI: 10.1007/164_2017_79] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
18 Kallupi M, Scuppa G, de Guglielmo G, Calò G, Weiss F, Statnick MA, Rorick-Kehn LM, Ciccocioppo R. Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction. Neuropsychopharmacology 2017;42:695-706. [PMID: 27562376 DOI: 10.1038/npp.2016.171] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
19 Asth L, Ruzza C, Malfacini D, Medeiros I, Guerrini R, Zaveri NT, Gavioli EC, Calo' G. Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands. Neuropharmacology 2016;105:434-42. [PMID: 26867504 DOI: 10.1016/j.neuropharm.2016.02.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
20 Methuku K, Li X, Cerne R, Gleason S, Schkeryantz J, Tiruveedhula V, Golani L, Li G, Poe M, Rahman M, Cook J, Fisher J, Witkin J. An antidepressant-related pharmacological signature for positive allosteric modulators of α2/3-containing GABA A receptors. Pharmacology Biochemistry and Behavior 2018;170:9-13. [DOI: 10.1016/j.pbb.2018.04.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Asth L, Tiago PRF, Costa LRF, Holanda VAD, Pacifico S, Zaveri NT, Calo' G, Ruzza C, Gavioli EC. Effects of non-peptide nociceptin/orphanin FQ receptor ligands on methylphenidate-induced hyperactivity in mice: Implications for bipolar disorders. Neuropeptides 2020;82:102059. [PMID: 32600667 DOI: 10.1016/j.npep.2020.102059] [Reference Citation Analysis]
22 Ferrari F, Cerlesi MC, Malfacini D, Asth L, Gavioli EC, Journigan BV, Kamakolanu UG, Meyer ME, Yasuda D, Polgar WE, Rizzi A, Guerrini R, Ruzza C, Zaveri NT, Calo G. In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations. Eur J Pharmacol 2016;793:1-13. [PMID: 27780725 DOI: 10.1016/j.ejphar.2016.10.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
23 Park JY, Chae S, Kim CS, Kim YJ, Yi HJ, Han E, Joo Y, Hong S, Yun JW, Kim H, Shin KH. Role of nociceptin/orphanin FQ and nociceptin opioid peptide receptor in depression and antidepressant effects of nociceptin opioid peptide receptor antagonists. Korean J Physiol Pharmacol 2019;23:427-48. [PMID: 31680765 DOI: 10.4196/kjpp.2019.23.6.427] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
24 Rorick-Kehn LM, Ciccocioppo R, Wong CJ, Witkin JM, Martinez-Grau MA, Stopponi S, Adams BL, Katner JS, Perry KW, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Pedregal C, Weiss F, Statnick MA. A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models. Alcohol Clin Exp Res 2016;40:945-54. [PMID: 27084498 DOI: 10.1111/acer.13052] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
25 Der-Avakian A, D'Souza MS, Potter DN, Chartoff EH, Carlezon WA Jr, Pizzagalli DA, Markou A. Social defeat disrupts reward learning and potentiates striatal nociceptin/orphanin FQ mRNA in rats. Psychopharmacology (Berl) 2017;234:1603-14. [PMID: 28280884 DOI: 10.1007/s00213-017-4584-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
26 Mercatelli D, Pisanò CA, Novello S, Morari M. NOP Receptor Ligands and Parkinson’s Disease. In: Ko M, Caló G, editors. The Nociceptin/Orphanin FQ Peptide Receptor. Cham: Springer International Publishing; 2019. pp. 213-32. [DOI: 10.1007/164_2018_199] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
27 Genovese RF, Dobre S. Mitigation of adverse behavioral impact from predator exposure by the nociceptin/orphanin FQ peptide antagonist J-113397 in rats. Behavioural Pharmacology 2017;28:521-30. [DOI: 10.1097/fbp.0000000000000329] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
28 Khan MS, Boileau I, Kolla N, Mizrahi R. A systematic review of the role of the nociceptin receptor system in stress, cognition, and reward: relevance to schizophrenia. Transl Psychiatry 2018;8:38. [PMID: 29391391 DOI: 10.1038/s41398-017-0080-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
29 Witkin JM, Rorick-Kehn LM, Benvenga MJ, Adams BL, Gleason SD, Knitowski KM, Li X, Chaney S, Falcone JF, Smith JW, Foss J, Lloyd K, Catlow JT, McKinzie DL, Svensson KA, Barth VN, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Pedregal C, Martínez-Grau MA, Post A, Ansonoff MA, Pintar JE, Statnick MA. Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors. Pharmacol Res Perspect 2016;4:e00275. [PMID: 28097008 DOI: 10.1002/prp2.275] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
30 da Silva JA, Biagioni AF, Almada RC, de Freitas RL, Coimbra NC. Panicolytic-like effects caused by substantia nigra pars reticulata pretreatment with low doses of endomorphin-1 and high doses of CTOP or the NOP receptors antagonist JTC-801 in male Rattus norvegicus. Psychopharmacology 2017;234:3009-25. [DOI: 10.1007/s00213-017-4678-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
31 Peciña M, Karp JF, Mathew S, Todtenkopf MS, Ehrich EW, Zubieta JK. Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Mol Psychiatry 2019;24:576-87. [PMID: 29955162 DOI: 10.1038/s41380-018-0117-2] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 19.7] [Reference Citation Analysis]
32 Witkin JM, Wallace TL, Martin WJ. Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094). In: Ko M, Caló G, editors. The Nociceptin/Orphanin FQ Peptide Receptor. Cham: Springer International Publishing; 2019. pp. 399-415. [DOI: 10.1007/164_2018_186] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
33 Ferrari F, Malfacini D, Journigan BV, Bird MF, Trapella C, Guerrini R, Lambert DG, Calo' G, Zaveri NT. In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403. Pharmacol Res Perspect 2017;5. [PMID: 28805972 DOI: 10.1002/prp2.333] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
34 Toll L, Cippitelli A, Ozawa A. The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies. CNS Drugs 2021;35:591-607. [PMID: 34057709 DOI: 10.1007/s40263-021-00821-0] [Reference Citation Analysis]
35 Mercatelli D, Bezard E, Eleopra R, Zaveri NT, Morari M. Managing Parkinson's disease: moving ON with NOP. Br J Pharmacol 2020;177:28-47. [PMID: 31648371 DOI: 10.1111/bph.14893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
36 Borruto AM, Fotio Y, Stopponi S, Petrella M, De Carlo S, Domi A, Ubaldi M, Weiss F, Ciccocioppo R. NOP receptor antagonism attenuates reinstatement of alcohol-seeking through modulation of the mesolimbic circuitry in male and female alcohol-preferring rats. Neuropsychopharmacology 2021. [PMID: 34285372 DOI: 10.1038/s41386-021-01096-1] [Reference Citation Analysis]
37 Yuen E, Swanson S, Witkin JM. Prediction of human efficacious antidepressant doses using the mouse forced swim test. Pharmacology Biochemistry and Behavior 2017;161:22-9. [DOI: 10.1016/j.pbb.2017.09.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
38 Pitsillou E, Bresnehan SM, Kagarakis EA, Wijoyo SJ, Liang J, Hung A, Karagiannis TC. The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression. Mol Biol Rep 2020;47:753-70. [PMID: 31612411 DOI: 10.1007/s11033-019-05129-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
39 Ferrari F, Rizzo S, Ruzza C, Calo G. Detailed In Vitro Pharmacological Characterization of the Clinically Viable Nociceptin/Orphanin FQ Peptide Receptor Antagonist BTRX-246040. J Pharmacol Exp Ther 2020;373:34-43. [PMID: 31937563 DOI: 10.1124/jpet.119.262865] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
40 Post A, Smart TS, Jackson K, Mann J, Mohs R, Rorick-kehn L, Statnick M, Anton R, O'malley SS, Wong CJ. Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence. Alcohol Clin Exp Res 2016;40:1935-44. [DOI: 10.1111/acer.13147] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
41 Li S, Luo H, Lou R, Tian C, Miao C, Xia L, Pan C, Duan X, Dang T, Li H, Fan C, Tang P, Zhang Z, Liu Y, Li Y, Xu F, Zhang Y, Zhong G, Hu J, Shui W. Multiregional profiling of the brain transmembrane proteome uncovers novel regulators of depression. Sci Adv 2021;7:eabf0634. [PMID: 34290087 DOI: 10.1126/sciadv.abf0634] [Reference Citation Analysis]
42 Holanda VAD, Pacifico S, Azevedo Neto J, Finetti L, Lobão-soares B, Calo G, Gavioli EC, Ruzza C. Modulation of the NOP receptor signaling affects resilience to acute stress. J Psychopharmacol 2019;33:1540-9. [DOI: 10.1177/0269881119864942] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
43 Holanda VAD, Santos WB, Asth L, Guerrini R, Calo’ G, Ruzza C, Gavioli EC. NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine. Psychopharmacology 2018;235:3093-102. [DOI: 10.1007/s00213-018-5004-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
44 Fulford AJ, Keskes S. Limbic circuit connectivity and the stress response: New insights into the mammalian nociceptin peptide system. Vitam Horm 2019;111:131-45. [PMID: 31421698 DOI: 10.1016/bs.vh.2019.05.002] [Reference Citation Analysis]
45 Reinscheid RK, Civelli O. The History of N/OFQ and the NOP Receptor. Handb Exp Pharmacol 2019;254:3-16. [PMID: 30689090 DOI: 10.1007/164_2018_195] [Reference Citation Analysis]
46 Browne CA, Jacobson ML, Lucki I. Novel Targets to Treat Depression: Opioid-Based Therapeutics. Harv Rev Psychiatry 2020;28:40-59. [DOI: 10.1097/hrp.0000000000000242] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 11.0] [Reference Citation Analysis]
47 Litten RZ. Nociceptin Receptor as a Target to Treat Alcohol Use Disorder: Challenges in Advancing Medications Development. Alcohol Clin Exp Res 2016;40:2299-304. [DOI: 10.1111/acer.13222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
48 Zaveri NT. Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility. J Med Chem 2016;59:7011-28. [PMID: 26878436 DOI: 10.1021/acs.jmedchem.5b01499] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 11.8] [Reference Citation Analysis]
49 Parker KE, Sugiarto E, Taylor AMW, Pradhan AA, Al-Hasani R. Pain, Motivation, Migraine, and the Microbiome: New Frontiers for Opioid Systems and Disease. Mol Pharmacol 2020;98:433-44. [PMID: 32958571 DOI: 10.1124/mol.120.119438] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 Jacobsen JPR, Krystal AD, Krishnan KRR, Caron MG. Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale. Trends Pharmacol Sci 2016;37:933-44. [PMID: 27692695 DOI: 10.1016/j.tips.2016.09.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
51 Gavioli EC, Holanda VAD, Ruzza C. NOP Ligands for the Treatment of Anxiety and Mood Disorders. Handb Exp Pharmacol 2019;254:233-57. [PMID: 30535941 DOI: 10.1007/164_2018_188] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
52 Bodnar RJ. Endogenous Opiates and Behavior: 2016. Peptides 2018;101:167-212. [DOI: 10.1016/j.peptides.2018.01.011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
53 Mchugh KL, Kelly JP. Modulation of the central opioid system as an antidepressant target in rodent models. The Opioid System as the Interface between the Brain’s Cognitive and Motivational Systems. Elsevier; 2018. pp. 49-87. [DOI: 10.1016/bs.pbr.2018.07.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
54 Toll L, Bruchas MR, Calo' G, Cox BM, Zaveri NT. Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems. Pharmacol Rev 2016;68:419-57. [PMID: 26956246 DOI: 10.1124/pr.114.009209] [Cited by in Crossref: 147] [Cited by in F6Publishing: 135] [Article Influence: 29.4] [Reference Citation Analysis]